Edwards Lifesciences (EW) Fundamental Analysis: Revenue, Earnings & Valuation

9.18 / 10

Outperform

Fundamental analysis scores 9.18/10, rating Outperform. Profit‑MV, ROE, ROA, cash‑flow ratios and margins rank in top quartiles, driving strong earnings quality. Asset‑MV lags, but its impact is limited. Overall fundamentals appear robust and attractive.

Analysis Checks(9/10)

ROA (%)

Value7.99

Score3/3

Weight22.68%

1M Return1.08%

Net cash flow from operating activities / Operating revenue (%)

Value26.29

Score3/3

Weight27.49%

1M Return1.24%

Profit-MV

Value0.18

Score3/3

Weight72.76%

1M Return3.42%

Cash-UP

Value-0.29

Score2/3

Weight-86.54%

1M Return-5.76%

Fixed assets turnover ratio

Value3.28

Score2/3

Weight-15.41%

1M Return-0.79%

Net cash flow from operating activities / Total liabilities (%)

Value0.47

Score3/3

Weight42.10%

1M Return1.90%

Annualized net profit margin on total assets (%)

Value7.99

Score3/3

Weight22.68%

1M Return1.08%

ROE (diluted) (%)

Value10.38

Score3/3

Weight22.70%

1M Return1.07%

Asset-MV

Value-0.55

Score1/3

Weight-29.30%

1M Return-1.56%

Cash-MV

Value-0.69

Score2/3

Weight20.84%

1M Return0.99%

Is EW fundamentally strong?

EW scores 9.18/10 on fundamentals and holds a Discounted valuation at present. Backed by its 10.52% ROE, 17.62% net margin, 42.61 P/E ratio, 4.42 P/B ratio, and -73.64% earnings growth, these metrics solidify its Outperform investment rating.